ZWI Therapeutics

ZWI Therapeutics, Inc. was founded in 2020 as a biotechnology company developing novel protein therapies using innovative zwitterionic polymers, polycarboxybetaine (pCB), as an alternative to polyethylene glycol (PEG). ZWI's technology is being developed into new, patented hydrophilic zwitterionic polymers that are available for human use across multiple platforms.